IMPORTANCE Long-acting muscarinic antagonists (LAMAs) are a potential adjunct therapy to inhaled corticosteroids in the management of persistent asthma.
D aily use of inhaled corticosteroids is the cornerstone of the management of persistent asthma. 1 As disease severity increases or control is determined to be suboptimal, current guidance suggests a stepwise approach in escalating therapy including increasing the inhaled corticosteroids dose, adding adjunctive therapies, or both. In patients 12 years and older, long-acting β-agonists (LABAs) are currently the preferred adjunctive therapy to inhaled corticosteroids. If control remains suboptimal, options include further increasing the inhaled corticosteroids dose and adding adjuncts such as biologics or oral corticosteroids. Such therapies expose patients to systemic effects of drugs and thus carry a risk of more significant adverse effects.
In 2014, the tiotropium soft mist inhaler was the first long-acting muscarinic antagonist (LAMA) approved for the maintenance of asthma. 2 Several clinical trials have evaluated LAMAs in the management of persistent asthma, a topic identified as a key area for which current guidelines will be updated. 3 The objective of this systematic review and meta-
analysis was to identify and analyze data comparing LAMA with placebo or with other controllers as an add-on therapy to inhaled corticosteroids and the use of a LAMA, inhaled corticosteroids, and LABA (hereafter referred to as triple therapy) vs inhaled corticosteroids and LABA in patients 12 years or older with uncontrolled, persistent asthma.
Methods
We developed and followed a standard protocol that was registered (PROSPERO 2016:CRD42016047985) and can be found online. 4 This systematic review and meta-analysis includes 3 of 6 research questions in the protocol. The other 3 questions examined the effect of intermittent inhaled corticosteroids in children with recurrent wheezing and children or adults with persistent asthma. The final full report addressing all 6 research questions is available on the Agency for Healthcare Research and Quality website. 5 
Data Sources and Searches
We searched MEDLINE (Ovid MEDLINE, Ovid MEDLINE In-Process and Other Nonindexed Citations), EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews via OVID from inception through August 2016, updated through November 28, 2017 (eAppendix A in the Supplement). We supplemented the bibliographic database searches with backward citation tracking of relevant publications. We searched http://www .clinicaltrials.gov and the World Health Organization International Controlled Trials Registry platform for ongoing studies and those completed with reported results. In addition, the Scientific Resource Center of the Agency for Healthcare Research and Quality requested data from manufacturers.
Study Selection
We included studies that evaluated patients 12 years and older with uncontrolled, persistent asthma 1 that compared LAMA vs placebo or vs another controller as an add-on therapy to inhaled corticosteroids or that compared triple therapy vs inhaled corticosteroids and LABA. We required that studies assess 1 of the following outcomes: asthma exacerbations (systemic corticosteroid use, hospitalization, emergency department visits, intensive care or intubation, or as defined by the study), mortality (all cause or asthma-specific), spirometry (measured as peak, trough, and area under the curve [ , and health care utilization (additional medication use, additional health resource use related to the intervention). Asthma worsening was defined by studies as a progressive increase in asthma symptoms compared with day-today symptoms or a decrease in morning peak expiratory flow (PEF) of 30% or more for 2 or more days. A responder was defined as having a decrease in ACQ score by 0.5 points or more 6 or increase in AQLQ score by 0.5 points or more. 7 A minimally important change in FEV 1 was defined as an increase or decrease of 0.2 L or more. 8 We considered for inclusion randomized clinical trials (RCTs; parallel group or crossover trials), prospective or retrospective observational cohort studies, and case-control studies. We included crossover trials if outcomes after the first treatment period were available or if the washout period was a minimum of 6 weeks for inhaled corticosteroids and 4 weeks for LAMA and LABA. We did not apply restrictions in publication language or date. We screened titles and abstracts using 2 independent investigators to determine if the citation met eligibility criteria. We reviewed full-text publications when both reviewers agreed a citation met eligibility criteria and resolved disagreements through consensus in consultation with a third reviewer. We contacted corresponding authors for clarification, when needed, to assess the inclusion criteria. We matched abstracts and meeting presentations to their corresponding fulltext publication and reviewed them for supplemental data. crossover trials when available, otherwise we contacted authors for period 1 outcomes. Two independent reviewers assessed risk of bias using the Cochrane Collaboration's Risk of Bias Tool for RCTs. 9 The following individual domains were assessed by 2 investigators as either low, unclear, or high risk of bias: (1) random sequence generation, (2) allocation sequence concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) completeness of outcome data, (6) selective reporting, and (7) other sources of bias.
Data Synthesis and Analysis
We based data synthesis on pharmacologic class (eg, LAMA, LABA, inhaled corticosteroids) rather than an individual drug. When a trial included more than 1 intervention group for the same drug but with different doses (eg, tiotropium 2.5 μg and 5 μg), we combined the groups into a single intervention group using recommended formulas. 10 Synthesis was also based on the age category of 12 years or older, consistent with the Expert Panel Report-3. 1 We conducted meta-analysis of RCTs using the Hartung-Knapp 11, 12 random-effects model to estimate risk ratios (RRs) and risk differences (RDs) with corresponding 95% CIs for binary outcomes and mean differences (MDs) with corresponding 95% CIs for continuous outcomes when data from 3 or more studies were available. We calculated the Peto odds ratio and 95% CIs for binary outcomes with rare events (<5%) in place of an RR. 13 We performed sensitivity analyses removing studies that had a high risk of bias in at least 1 of the 7 domains (eg, a lack of participant or personnel blinding). We assessed presence of statistical heterogeneity using the Cochrane P value (P < .10 for significance) and the degree of heterogeneity using the I 2 statistic with a value more than 50% considered substantial. 14 We planned to assess publication bias using funnel plot inspection and tests of plot asymmetry when 10 or more trials were pooled. 15 However, none of the pooled analysis reached this threshold.
To explore sources of heterogeneity, we performed subgroup analysis when 3 or more trials per subgroup were available for a given outcome. We qualitatively summarized included studies when they were not amenable to pooling.
All analyses were performed using the meta package in R (version 3.4.3; the R Project for Statistical Computing).
Strength of Evidence
We evaluated the strength of evidence as high, moderate, low, or insufficient based on established guidance. 16 Two senior investigators assessed strength of evidence independently and then, through discussion, arrived at the final grading based on 5 required domains: risk of bias, consistency, directness, precision, and publication bias. A more thorough discussion of this process can be found in eAppendix B in the Supplement.
Results
Fifty-eight citations that represented 15 unique RCTs 17-29 and 7122 participants (of which 789 were adolescents) were included in the analysis ( Figure 1 
Risk of Bias

LAMA vs Other Controllers as Add-on Therapy to Inhaled Corticosteroids
The majority of identified data compared adding LAMA vs LABA to inhaled corticosteroids ( Figure 3A , eFigures 6-10 in the Supplement). No significant associations with FEV 1 peak were seen (eFigure 6 in the Supplement). No significant association with AQLQ score or AQLQ score response was seen with triple therapy. Triple therapy was not significantly associated with improvements in rescue medication use vs combined inhaled corticosteroids and LABA therapy ( Figure 3B ). A single trial compared triple therapy vs increasing the inhaled corticosteroids dose administered with a LABA and found no significant association with ACT scores.
Subgroup and Sensitivity Analysis
Preplanned subgroup analysis based on tiotropium dose did not suggest any substantial associations with either dose compared with placebo or with each other (eTable 4 in the Supplement). When we removed studies with components of high risk of bias, the overall findings remained consistent (eTable 5 in the Supplement). Because the duration of follow-up was shorter in the study by Lee et al 19 (15 days),
we conducted post hoc meta-regression analyses for outcomes including this study. No significant association between any outcomes and study duration was seen (P > .05 for all) (eFigures 12-17 in the Supplement).
Discussion
In this systematic review and meta-analysis, the addition of LAMA to inhaled corticosteroids maintenance therapy for the ACQ-7 indicates 7-Item Asthma Control Questionnaire; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; MD, mean difference; RR, risk ratio. Size of the data markers indicates the weight of the study. For continuous outcomes, the mean value represents the mean change from baseline (change score) for each study group and the MD value represents the difference in change scores (change from baseline) between the LAMA and control groups. The I 2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range, 0%-100%), and the P value is a test of heterogeneity across all studies (P <.10 indicates likely variation across pooled estimates related to statistical heterogeneity). "Events" indicates the number of participants in each group who experienced an event. ACQ-7 (range, 0 [worse] to 6 [better control]) is a patient self-administered tool for assessing overall asthma control. The minimal important difference was 0.5 for the ACQ7 and 0.2 L for the FEV 1 .
Research Original Investigation
Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Uncontrolled Asthma Final health outcomes important in the management of asthma include the reduction of exacerbation and mortality risk. Exacerbations were almost exclusively reported as those that require systemic corticosteroids and LAMA was associated with a significant 47% reduction in risk when added to inhaled corticosteroids vs adding placebo, when the inhaled corticosteroids dose was held constant. LAMA was not significantly associated with the risk of exacerbation compared with doubling the dose of inhaled corticosteroids, with LABA as an add-on therapy to inhaled corticosteroids, or with triple therapy with the inhaled corticosteroids dose remaining the same in a population of patients that had severe persistent asthma considered of highest risk of exacerbations. In the trials evaluating triple therapy, patients were also permitted to continue use of stable doses of other controllers; thus, results are most applicable to a similar patient group. Other definitions of exacerbations were rare and did not suggest difference in association for any of the comparisons made. Deaths did not occur in the trials that reported this outcome, with the exception of 1 trial that compared LAMA vs LABA as add-on therapy to inhaled corticosteroids in which asthma-related deaths were infrequent over 18 months. However, most other trials did not exceed 6 months of duration and thus were limited in the reporting of such final health outcomes.
Spirometry is considered a core outcome to measure asthma severity, control, and response to therapy and both FEV 1 and FVC are responsive to bronchodilators. 35 When LAMA was added to inhaled corticosteroids vs placebo with the inhaled corticosteroids dose remaining the same, significant associations with improved measures of FEV 1 and FVC were seen. Similarly, significant improvements in FVC measures were associated with triple therapy whereas measures of FEV 1 trended in the same direction. Despite these positive associations, none of the results for FEV 1 reached the minimally important difference of 0.2 L. 8 There were no significant associations with improvements in spirometry between LAMA and LABA as an add-on therapy to inhaled corticosteroids, suggesting that bronchodilation is not significantly different between these 2 therapies. Given the association with small numerical improvements in spirometry with LAMA, it is reasonable to expect similar improvements in other measures of asthma control. Rescue medication use (measured as puffs per 24 hours) was not significantly associated with LAMA regardless of the comparator. Moreover, the mean difference in ACQ-7 score, which is a preferred tool to measure asthma control, 36 was also not significantly associated with LAMA vs any other comparator. Prior research suggests the lack of improvement in ACQ score is consistent in trials studying the effect of another controller added on to inhaled corticosteroids therapy and further suggests the need for investigators to conduct responder analysis. 37 In this systematic review, improvements in ACQ responder analysis was not significantly associated with LAMA added to inhaled corticosteroids vs placebo, nor was there an association when comparing LAMA with LABA as an add-on therapy to inhaled corticosteroids. However, a consistently positive association was seen with triple therapy for ACQ score response, and a similar pattern found for asthma-related quality of life. Thus, although triple therapy was not associated with a reduced exacerbation risk in this systematic review, patient-important outcomes such as symptom control and quality of life were favorable.
Applicability
The target population for this review included an age group of 12 years and older, with uncontrolled, persistent asthma. This age category was chosen to be consistent with the current Expert Panel Report-3. 1 All but 2 studies included in this review enrolled adults 18 years and older, and the mean age was generally in the fourth decade; most studies excluded patients older than the sixth to seventh decade. The 2 included trials 22,28 specific to adolescents were in general agreement with the findings of this systematic review suggesting LAMA vs placebo as add-on therapy to inhaled corticosteroids is associated with numerically improved lung function although statistical significance was not achieved in the 1 trial of 12 weeks duration. Both trials cite profound placebo effects that may be a Meta-analyses were performed when Ն3 studies reported the same outcome. When data were available for Յ2 studies, the results from each study are individually shown. For continuous outcomes, the mean value represents the mean change from baseline (change score) for each study group and the MD represents the difference in change scores (change from baseline) between the LAMA and control groups.
b Data are presented as either number of participants with an event (for dichotomous end points) or mean (SD) value (for continuous end points).
c Data are presented as absolute risk differences (risk in LAMA group minus risk in control group) between groups.
d The strength of evidence for each study was based on 5 domains (risk of bias, consistency, directness, precision, and publication bias) and categorized as high, moderate, low, or insufficient (eAppendix B in the Supplement).
e Defined by studies as a progressive increase in asthma symptoms compared with day-to-day symptoms or a decrease in morning peak expiratory flow of Ն30% for Ն2 days. f ACQ responder was defined as an individual who had their score improve by Ն0.5 points.
6 ACQ (range, 0 [worse] to 6 [better control]) is a patient self-administered tool for assessing overall asthma control. The minimal important difference is a 0.5-point change. asthma-specific quality of life tool. The minimal important difference is a 0.5-point change. 7,32-34 AQLQ responder was defined as an individual who had their score improve by Ն0.5 points . 7 
Research Original Investigation
Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Uncontrolled Asthma explained by improved inhaled corticosteroids adherence due to the trial environment. 37 Although statistical heterogeneity was low in all of the analyses within this review, the applicability of results in this systematic review may not fully reflect the breadth of ages that require asthma management, including adolescents and elderly persons. The literature base included in this systematic review is almost exclusive to 1 LAMA-tiotropium. Other LAMAs, such as aclidinium and glycopyrronium, are approved for other indications. One study in this systematic review evaluated glycopyrronium, but the trial was a crossover and thus contributed period 1, which was only 15 days. In the future, if additional LAMAs come to the market for asthma management, there may be value in having their efficacy individually assessed and compared with findings of this review. Several clinical trials are ongoing (NCT02676089, NCT02676076, NCT02433834, NCT02382510) related to other LAMAs in asthma management and will provide future evidence in this area.
Of the various subgroups of interest defined a priori, data was only sufficient for the analyses based on tiotropium dose. Analysis in this systematic review did not show significant associations for tiotropium doses of 2.5 μg and 5 μg for any outcome. Multigroup trials have compared both doses of tiotropium with placebo and have assessed if the change is greater numerically with 5 μg vs placebo or 2.5 μg vs placebo without formal statistical testing. Studies have found inconsistent effects with some data suggesting a numerically greater improvement with 5 μg vs placebo whereas others suggest 2.5 μg produces a numerically greater improvement vs placebo. 18, [20] [21] [22] In the absence of formal indirect statistical comparison, subgroup analysis in the current systematic review suggests a lack of association between these 2 doses. Future trials should consider reporting data on other subgroups of interest as well, including those determined by expert panelists to be of most importance within this review, and routinely report such results numerically to help decision makers reach more individualized treatment decisions.
Trials included in this systematic review defined uncontrolled asthma based on the ACQ score. However, this is only 1 of many criteria recommended for assessment. 1 Likewise, although all patients were considered to have persistent asthma given their use of inhaled corticosteroids maintenance therapy, whether patients had mild, moderate, or severe persistent asthma was left to the reporting of the study authors. Future studies would benefit from consistently defining the severity and control of asthma in the recruited population to facilitate evaluation of various degrees of severity. There are many potential reasons a patient may be considered to have uncontrolled asthma and these may provide insight into preference for a particular treatment. Future studies should focus on these various causes of uncontrolled asthma as part of investigation for alternative treatments. Knowing more about the severity and control of enrolled participants would also enhance applicability of evidence.
Limitations
This study has several limitations. First, this systematic review did not address harms or costs associated with LAMA or the other pharmacotherapies of interest because they were not within the scope of the review. However, when selecting appropriate therapy for patients, decision makers should consider known harms and costs of these drug therapies. Second, at the time that this review was designed and conducted, tiotropium was approved for patients 12 years and older. Recently, tiotropium has been approved in patients as young as 6 years; thus, this younger age group is not reflected in the current findings. Third, although there were many subgroups of interest, analyses could not be conducted on most of them due to the lack of reported data or relatively few trials with reported data. This limits the ability of decision makers to further individualize recommendations. Fourth, conclusions regarding the comparison of LAMA with controllers other than LABA as add-on therapy to inhaled corticosteroids could not be made given a relatively small amount of data that was also limited in outcomes. Fifth, due to the number of outcomes that were evaluated, type I error cannot be ruled out for statistically significant associations. Sixth, the included trials used efficacy designs; it is unclear whether evidence from real-world settings would provide similar results.
Conclusions
In this systematic review and meta-analysis, the use of LAMA compared with placebo as add-on therapy to inhaled corticosteroids was associated with a lower risk of asthma exacerbations; however, the association of LAMA with benefit may not be greater than that with LABA. Triple therapy was not associated with a lower risk of exacerbations.
collection, management, analysis or interpretation of the data; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication.  Risk of bias: The overall pattern within the 7 risk of bias domains was considered along with how much the individual study contributed to the overall analysis sample size.  Consistency: Consistency refers to the degree of similarity in the direction of effects (do all studies show the same effect, e.g. all superior or all null) and the magnitude of effect (the degree to which point estimates are similar) across studies within an evidence base. The magnitude of effect is often evaluated quantitatively using test for the presence (e.g., Cochran's Q tes) or the magnitude of heterogeneit (e.g., I
2 statistic).  Directness: Directness of evidence expresses how closely available evidence measures an outcome of interest, both in the directness of the outcome and the comparison. This represents a slingle link between an intervention and the outcome. Comparisons are considered direct when the studies compare interventions specifically with each other.  Precision: Precision is the degree of certainty surrounding an estimate of effect with respect to an outcome.
A precise body of evidence should enable decisionmakers to draw conclusions about whether one treatment is superior, inferior, or equivalent to another. For continuous outcomes, we used the minimally important difference (where available) for each outcome and whether confidence intervals crossed that threshold. For dichotomous outcomes, we used a relative risk increase or reuction of 0.25 from the point estimate. If the confidence interval crossed these thresholds, the outcome was comparison/outcome was considered imprecise.  Publication bias: Publication bias occurs when a decision is made to publish or report research findings based on their direction or magnitude of effect. Visual evaluations of funnel plots and tests for plot asymmetry were considered. Significant evaluations and tests were deemed to have positive publication bias.
Using evaluations of the 5 domains above, strength of evidence for each comparison and outcome was defined as:
 High: We are very confident that the estimate of effect lies close to the true effect for this outcome. The body of evidence has few or no deficiencies. We believe that the findings are stable, i.e., another study would not change the conclusions.  Moderate: We are moderately confident that the estimate of effect lies close to the true effect for this outcome. The body of evidence has some deficiencies. We believe the findings are likely to be stable, but some doubt remains.  Low: We have limited confidence that the estimate of effect lies close to the true effect for this outcome.
The body of evidence has major or numerous deficiencies (or both). We believe that additional evidence is needed before concluding either that the findings are stable or that the estimate of effect is close to the true effect.  Insufficient: We have no evidence, we are unable to estimate an effect, or we have no confidence in the estimate of the effect for this outcome. No evidence is available of the body of evidence has unacceptable deficiencies, precluding reaching a conclusion.
The strength of evidence was downgraded when one or more of the five domains above were noted. Data at baseline, randomized treatments were add-on to continued use of ICS c Concurrent therapy during the study with leukotriene modifiers was 7.1% in the tiotropium 5g daily arm, 9.7% in the tiotropium 2.5g daily arm, 8.3% in the salmeterol 50g BID arm and 7.5% in the placebo arm d
Concurrent therapies during the study in the tiotropium 2.5g daily arm included LABAs (54.4%), leukotriene modifiers (31.6%) and methylxanthines (22.8%). Concurrent therapies during the study in the tiotropium 5g daily arm included LABAs (57.0%), leukotriene modifiers (25.4%) and methylxanthines (16.7%). Concurrent therapies during the study in the placebo arm included LABAs (61.4%), leukotriene modifiers (24.6%) and methylxanthines (17.5%). Budesonide equipotent dose in g f Concurrent therapies during the study in the tiotropium arm included leukotriene modifiers (16.4%), theophylline (14.2%), omalizumab (2.7%), systemic steroids (3.7%) and antihistamines (14.2%). Concurrent therapies during the study in the placebo arm included leukotriene modifiers (19.7%), theophylline (12.8%), omalizumab (6.0%), systemic steroids (5.6%) and antihistamines (8.1%) g Data reported as mean (standard error) h ICS dose assumed due to fixed dosing with add-on therapy (tiotropium arm) or increased dose (salmeterol/fluticasone arm) used in trial i Concurrent therapies during the treatment period in the tiotropium 5g arm were systemic corticosteroids (3%), short acting anticholinergic (0.8%), long-acting 2-agonists (82.3%), theophylline (6.2%) and leukotriene modifiers (78.5%). In this arm, 33.1% of patients were on 2 controllers while 66.9% were on three controllers. Concurrent therapies during the treatment period in the tiotropium 2.5g arm were systemic corticosteroids (0.8%), long-acting 2-agonists (79.5%), theophylline (4.7%) and leukotriene modifiers (81.9%). In this arm, 33.9% of patients were on 2 controllers while 66.1% were on three controllers. Concurrent therapies during the treatment period in the placebo arm were systemic corticosteroids (1.5%), long-acting 2-agonists (85.9%), theophylline (5.2%) and leukotriene modifiers (80.7%). In this arm, 28.2% of patients were on 2 controllers while 71.9% were on three controllers Box sizes are proportional to study weight (box center positioned at point estimate of effect). The mean value represents the mean change from baseline (change score) for each study group and the mean difference (MD) value represents the difference in change scores (change from baseline) between the LAMA and Control groups. Horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range 0-100%), and the pvalue is a test of heterogeneity across all studies (p value < 0.10 indicates likely variation across pooled estimates related to statistical heterogeneity). A minimally important change in FEV1 was defined as an increase or decrease of 0.2 liters or more. 15 Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; MD, mean difference; SD, standard deviation eFigure 6. FEV1 AUC (L)
Box sizes are proportional to study weight (box center positioned at point estimate of effect). The mean value represents the mean change from baseline (change score) for each study group and the mean difference (MD) value represents the difference in change scores (change from baseline) between the LAMA and Control groups. Horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range 0-100%), and the pvalue is a test of heterogeneity across all studies (p value < 0.10 indicates likely variation across pooled estimates related to statistical heterogeneity). A minimally important change in FEV1 was defined as an increase or decrease of 0.2 liters or more. 15 Abbreviations: AUC, area under the curve; CI, confidence interval; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; MD, mean difference; SD, standard deviation eFigure 7. FEV1 % predicted Box sizes are proportional to study weight (box center positioned at point estimate of effect). The mean value represents the mean change from baseline (change score) for each study group and the mean difference (MD) value represents the difference in change scores (change from baseline) between the LAMA and Control groups. Horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range 0-100%), and the pvalue is a test of heterogeneity across all studies (p value < 0.10 indicates likely variation across pooled estimates related to statistical heterogeneity).
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; MD, mean difference; SD, standard deviation Box sizes are proportional to study weight (box center positioned at point estimate of effect). The mean value represents the mean change from baseline (change score) for each study group and the mean difference (MD) value represents the difference in change scores (change from baseline) between the LAMA and Control groups. Horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range 0-100%), and the pvalue is a test of heterogeneity across all studies (p value < 0.10 indicates likely variation across pooled estimates related to statistical heterogeneity). A minimally important change in FVC was defined as an increase or decrease of 0.2 liters or more. 15 Abbreviations: CI, confidence interval; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, longacting beta-agonist; LAMA, long-acting muscarinic antagonist; MD, mean difference; SD, standard deviation eFigure 9. FVC trough (L)
Box sizes are proportional to study weight (box center positioned at point estimate of effect). The mean value represents the mean change from baseline (change score) for each study group and the mean difference (MD) value represents the difference in change scores (change from baseline) between the LAMA and Control groups. Horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range 0-100%), and the pvalue is a test of heterogeneity across all studies (p value < 0.10 indicates likely variation across pooled estimates related to statistical heterogeneity). A minimally important change in FVC was defined as an increase or decrease of 0.2 liters or more. 15 Abbreviations: CI, confidence interval; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, longacting beta-agonist; LAMA, long-acting muscarinic antagonist; MD, mean difference; SD, standard deviation eFigure
FVC AUC (L)
Box sizes are proportional to study weight (box center positioned at point estimate of effect). The mean value represents the mean change from baseline (change score) for each study group and the mean difference (MD) value represents the difference in change scores (change from baseline) between the LAMA and Control groups. Horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range 0-100%), and the pvalue is a test of heterogeneity across all studies (p value < 0.10 indicates likely variation across pooled estimates related to statistical heterogeneity). A minimally important change in FVC was defined as an increase or decrease of 0.2 liters or more. 15 Abbreviations: AUC, area under the curve; CI, confidence interval; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; MD, mean difference; SD, standard deviation eFigure 11. AQLQ score Box sizes are proportional to study weight (box center positioned at point estimate of effect). The mean value represents the mean change from baseline (change score) for each study group and the mean difference (MD) value represents the difference in change scores (change from baseline) between the LAMA and Control groups. Horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range 0-100%), and the pvalue is a test of heterogeneity across all studies (p value < 0.10 indicates likely variation across pooled estimates related to statistical heterogeneity). AQLQ (range 1 [severe impairment] to 7 [no impairment] is an asthma-specific quality of life tool. The minimal important difference is a 0.5 point change. 16, 17 Abbreviations: AQLQ, Asthma Quality of Life Questionnaire; CI, confidence interval; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; MD, mean difference; SD, standard deviation eFigure 17. Metaregression for Association of Rescue Medication Use (puffs/24h) with Duration of Study (n=7) Follow-up (LAMA vs. LABA as add-on to ICS) This is a scatter plot with the change in rescue medication use (puffs/24h) for each study on the y-axis and the duration of study follow-up (weeks) on the x-axis. Each blue bubble represents a study in the analysis with the size of the bubble being inversely proportional to the variance of the estimated treatment effect. The mean difference (MD) value represents the difference in change scores (change from baseline) between the LAMA and Control groups. For this analysis, duration of study follow-up was not associated with a change in exacerbation risk (p=0.67).
